BACKGROUND Patients with moderate-to-severe chronic kidney disease (CKD) are poorly represented in clinical trials
These landmark studies either excluded or did not report outcomes among patients with advanced (stages 3b to 5) CKD (7) . Data on CRT in advanced CKD are currently limited to small, retrospective, singlecenter studies (8, 9 ) and a single meta-analysis (10) .
Concerns regarding the potential for decreased CRT efficacy and increased complications may lower the rate of CRT use in patients with advanced CKD. Thus, optimal device strategy for this population remains unclear (11) and variability in practice exists (12) . (14) . This approach has led to >90% accuracy for data elements (15) .
M e d i c a r e d a t a b a s e . Longitudinal outcomes
were obtained by linking fee-for-service Medicare claims to the ICD registry using a previously validated methodology (16) We subsequently assessed for an interaction between baseline characteristics (including CKD class) and the association between CRT-D and
outcomes with multivariable models with adjustment for all covariates in models; we adjusted for CKD in all models where CKD class was not the variable of interest. We reported hazard ratios (HR)
or subdistribution HR and their 95% confidence intervals (CIs) based on robust sandwich variance estimates to account for clustering of patients within hospitals. A p value of <0.05 was considered statistically significant for all tests. Analyses were performed using SAS (version 9.3, SAS institute, Cary, North Carolina). Table 1 .
RESULTS

Between
Logistic regression analyses (Online Table 1 We assessed rates of in-hospital, 30-day, and 90-day complication rates across CKD subgroups.
There was no significant difference in total inhospital, 30-day, or 90-day complications among CRT-D or ICD recipients across CKD subgroups ( Table 2) Table 3) . Notably, the cohorts resulting from the inverse probability-weighted estimators analyses were well balanced with regard to baseline patient characteristics, demonstrating adequate statistical adjustment for all measured baseline characteristics (Online Table 2 ). When subgroup analyses by CKD stage were performed in the LBBB-only population (Online Table 3), we found results similar to those found in the overall population (Central Illustration). There was no interaction between QRS duration, device type, and outcome.
Friedman et al.
CRT in Advanced CKD Values are n (%). *Trend across CKD stages, within designated device category. †Between device type and outcome, within the overall population. ‡Hematoma, pneumothorax, and tamponade or pericardial effusion requiring pericardiocentesis. §Mechanical complications, device infection.
Abbreviations as in Table 1 .
Friedman et al. Values are n (%) unless otherwise noted. *Adjusted using inverse probability-weighted Cox proportional hazard or Fine-Gray models, as appropriate. †Hazard ratio. ‡Sub-distribution hazard ratio. §For 10,348 pre-ESRD patients, including 9,038 CRT patients.
CI ¼ confidence interval; ESRD ¼ end-stage renal disease; HF ¼ heart failure; HR ¼ hazard ratio; other abbreviations as in Table 1 .
Prior studies have suggested that more severe renal dysfunction was associated with increased risk of device-related complications (23) (24) (25) 
